February 3, 2022. Phase 2 study posted in Clinical Trials.gov NCT05221502 Safety and efficacy of 4 months combination treatment for patients with drug sensitive TB:

    Delamanid + Bedaquiline + OPC-167832 10 mg

    Delamanid + Bedaquiline + OPC-167832 30 mg

    Delamanid + Bedaquiline + OPC-167832 90 mg